Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Diabetic"

212 News Found

Daewoong  completes combination therapy of antidiabetic drug Enavogliflozin
News | February 27, 2022

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Network18 Group and Novartis India launch ‘Netra Suraksha’ to raise awareness around diabetic eye diseases
Events | November 27, 2021

Network18 Group and Novartis India launch ‘Netra Suraksha’ to raise awareness around diabetic eye diseases

The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly


NPPA fixes ceiling price for anti-diabetic generic medicines
Policy | October 26, 2021

NPPA fixes ceiling price for anti-diabetic generic medicines

A total of 12 generic medicines have been included in the list


QMS Medical partners with ZEISS for screening diabetic retinopathy
Medical Device | September 27, 2021

QMS Medical partners with ZEISS for screening diabetic retinopathy

Remote screening of diabetic retinopathy can help in early detection, even before there are any noticeable vision changes


Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra
News | October 08, 2025

Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra

Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025


Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada
News | September 22, 2025

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada


Nanavati Max Hospital performs 4-hour simultaneous pancreas-kidney transplant on 25-year-old with Type-1 diabetes
Healthcare | August 26, 2025

Nanavati Max Hospital performs 4-hour simultaneous pancreas-kidney transplant on 25-year-old with Type-1 diabetes

The complex four-hour surgery was performed by a multidisciplinary team of doctors